Efficacy and Safety of Ezetimibe Added on to Atorvastatin (40 mg) Compared With Uptitration of Atorvastatin (to 80 mg) in Hypercholesterolemic Patients at High Risk of Coronary Heart Disease

American Journal of Cardiology

Volumn 102, Issue 11, 2008, Pages 1495-1501

  Leiter, Lawrence A ^a   Bays, Harold ^b   Conard, Scott ^c   Bird, Steven ^d   Rubino, Joseph ^d   Hanson, Mary E ^d   Tomassini, Joanne E ^d   Tershakovec, Andrew M ^d  

^a ST MICHAEL'S HOSPITAL   (Canada)

^b LOUISVILLE METABOLIC AND ATHEROSCLEROSIS RESEARCH CENTER   (United States)

^c UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^d MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; APOLIPOPROTEIN A1; APOLIPOPROTEIN B; ASPARTATE AMINOTRANSFERASE; ATORVASTATIN; CREATINE KINASE; EZETIMIBE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ADD ON THERAPY; ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY RISK; CREATINE KINASE BLOOD LEVEL; DOUBLE BLIND PROCEDURE; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG WITHDRAWAL; FEMALE; GALLBLADDER DISEASE; GASTROINTESTINAL SYMPTOM; HEPATITIS; HUMAN; HYPERCHOLESTEROLEMIA; ISCHEMIC HEART DISEASE; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH; RISK REDUCTION; SIDE EFFECT; TRIACYLGLYCEROL BLOOD LEVEL;

ANTICHOLESTEREMIC AGENTS; AZETIDINES; CHOLESTEROL, LDL; CORONARY ARTERY DISEASE; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; HEPTANOIC ACIDS; HUMANS; HYPERCHOLESTEROLEMIA; MALE; MIDDLE AGED; PYRROLES; RISK ASSESSMENT; TREATMENT OUTCOME;

EID: 58149472552     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjcard.2008.09.076     Document Type: Article

References (28)

1. Pearson T.A., Laurora I., Chu H., and Kafonek S. The Lipid Treatment Assessment Project (L-TAP): a multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goals. Arch Intern Med 160 (2000) 459-467
2. Grundy S.M., Cleeman J.I., Merz C.N., Brewer Jr. H.B., Clark L.T., Hunninghake D.B., Pasternak R.C., Smith Jr. S.C., and Stone N.J. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. J Am Coll Cardiol 44 (2004) 720-732
3. Davidson M.H., Maki K.C., Pearson T.A., Pasternak R.C., Deedwania P.C., McKenney J.M., Fonarow G.C., Maron D.J., Ansell B.J., Clark L.T., and Ballantyne C.M. Results of the National Cholesterol Education (NCEP) Program Evaluation ProjecT Utilizing Novel E-Technology (NEPTUNE) II survey and implications for treatment under the recent NCEP Writing Group recommendations. Am J Cardiol 96 (2005) 556-563
4. Parke-Davis. Lipitor (atorvastatin calcium) tablets [package insert] (2007), Parke-Davis, New York
5. Bristol-Myers Squibb. Pravachol (pravastatin sodium) tablets [package insert] (2007), Bristol-Myers Squibb, Princeton, NJ
6. Merck & Co. Inc. Zocor (simvastatin) tablets [package insert] (2007), Merck & Co. Inc, Whitehouse Station, NJ
7. Jones P.H., Davidson M.H., Stein E.A., Bays H.E., McKenney J.M., Miller E., Cain V.A., and Blasetto J.W. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* Trial). Am J Cardiol 92 (2003) 152-160
8. AstraZeneca. Crestor (rosuvastatin calcium) tablets [package insert] (2007), AstraZeneca, Wilmington, DE
9. Sudhop T., Lutjohann D., Kodal A., Igel M., Tribble D.L., Shah S., Perevozskaya I., and von Bergmann K. Inhibition of intestinal cholesterol absorption by ezetimibe in humans. Circulation 106 (2002) 1943-1948
10. Dujovne C.A., Ettinger M.P., McNeer J.F., Lipka L.J., LeBeaut A.P., Suresh R., Yang B., and Veltri E.P. Efficacy and safety of a potent new selective cholesterol absorption inhibitor, ezetimibe, in patients with primary hypercholesterolemia. Am J Cardiol 90 (2002) 1092-1097
11. Knopp R.H., Gitter H., Truitt T., Bays H., Manion C.V., Lipka L.J., LeBeaut A.P., Suresh R., Yang B., and Veltri E.P. Effects of ezetimibe, a new cholesterol absorption inhibitor, on plasma lipids in patients with primary hypercholesterolemia. Eur Heart J 24 (2003) 729-741
12. Lammert F., and Wang D.Q. New insights into the genetic regulation of intestinal cholesterol absorption. Gastroenterology 129 (2005) 718-734
13. Gagne C., Bays H.E., Weiss S.R., Mata P., Quinto K., Melino M., Cho M., Musliner T.A., and Gumbiner B. Efficacy and safety of ezetimibe added to ongoing statin therapy for treatment of patients with primary hypercholesterolemia. Am J Cardiol 90 (2002) 1084-1091
14. Davidson M.H., McGarry T., Bettis R., Melani L., Lipka L.J., LeBeaut A.P., Suresh R., Sun S., and Veltri E.P. Ezetimibe coadministered with simvastatin in patients with primary hypercholesterolemia. J Am Coll Cardiol 40 (2002) 2125-2134
15. Ballantyne C.M., Houri J., Notarbartolo A., Melani L., Lipka L.J., Suresh R., Sun S., LeBeaut A.P., Sager P.T., and Veltri E.P. Effect of ezetimibe coadministered with atorvastatin in 628 patients with primary hypercholesterolemia: a prospective, randomized, double-blind trial. Circulation 107 (2003) 2409-2415
16. Goldberg A.C., Sapre A., Liu J., Capece R., and Mitchel Y.B. Efficacy and safety of ezetimibe coadministered with simvastatin in patients with primary hypercholesterolemia: a randomized, double-blind, placebo-controlled trial. Mayo Clin Proc 79 (2004) 620-629
17. Feldman T., Koren M., Insull Jr. W., McKenney J., Schrott H., Lewin A., Shah S., Sidisin M., Cho M., Kush D., and Mitchel Y. Treatment of high-risk patients with ezetimibe plus simvastatin co-administration versus simvastatin alone to attain National Cholesterol Education Program Adult Treatment Panel III low-density lipoprotein cholesterol goals. Am J Cardiol 93 (2004) 1481-1486
18. Pearson T.A., Denke M.A., McBride P.E., Battisti W.P., Brady W.E., and Palmisano J. A community-based, randomized trial of ezetimibe added to statin therapy to attain NCEP ATP III goals for LDL cholesterol in hypercholesterolemic patients: the Ezetimibe Add-on to Statin for Effectiveness (EASE) trial. Mayo Clin Proc 80 (2005) 587-595
19. Masana L., Mata P., Gagne C., Sirah W., Cho M., Johnson-Levonas A.O., Meehan A., Troxell J.K., and Gumbiner B. Long-term safety and tolerability profiles and lipid-modifying efficacy of ezetimibe coadministered with ongoing simvastatin treatment: a multicenter, randomized, double-blind, placebo-controlled, 48-week extension study. Clin Ther 27 (2005) 174-184
20. Davidson M.H., Ballantyne C.M., Kerzner B., Melani L., Sager P.T., Lipka L., Strony J., Suresh R., and Veltri E. Efficacy and safety of ezetimibe coadministered with statins: randomised, placebo-controlled, blinded experience in 2382 patients with primary hypercholesterolemia. Int J Clin Pract 58 (2004) 746-755
21. Expert Panel on Detection Evaluation and Treatment of High Blood Cholesterol in Adults. Executive Summary of the Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 285 (2001) 2486-2497
22. Grundy S.M., Cleeman J.I., Daniels S.R., Donato K.A., Eckel R.H., Franklin B.A., Gordon D.J., Krauss R.M., Savage P.J., Smith Jr. S.C., Spertus J.A., and Costa F. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 112 (2005) 2735-2752
23. Liang K.Y., and Zeger S.L. Longitudinal data analysis of continuous and discrete responses for pre-post designs. Sankya Series B 62 (2000) 134-148
24. Miettinen O., and Nurminen M. Comparative analysis of two rates. Stat Med 4 (1985) 213-226
25. Stein E., Stender S., Mata P., Sager P., Ponsonnet D., Melani L., Lipka L., Suresh R., Maccubbin D., and Veltri E. Achieving lipoprotein goals in patients at high risk with severe hypercholesterolemia: efficacy and safety of ezetimibe co-administered with atorvastatin. Am Heart J 148 (2004) 447-455
26. Merck/Schering-Plough Pharmaceuticals. Zetia (ezetimibe) [package insert] (2008), Merck/Schering-Plough Pharmaceuticals, North Wales, PA
27. Melani L., Mills R., Hassman D., Lipetz R., Lipka L., LeBeaut A., Suresh R., Mukhopadhyay P., and Veltri E. Efficacy and safety of ezetimibe coadministered with pravastatin in patients with primary hypercholesterolemia: a prospective, randomized, double-blind trial. Eur Heart J 24 (2003) 717-728
28. Bissonnette S., Habib R., Sampalis F., Boukas S., and Sampalis J.S. Efficacy and tolerability of ezetimibe 10 mg/day coadministered with statins in patients with primary hypercholesterolemia who do not achieve target LDL-C while on statin monotherapy: A Canadian, multicentre, prospective study-the Ezetrol Add-On Study. Can J Cardiol 22 (2006) 1035-1044